Drug Profile

VS 013

Alternative Names: VS013

Latest Information Update: 29 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Florida Research Foundation
Developer Nuvara Therapeutics
Class Amino acids; Irritable bowel syndrome therapies
Mechanism of Action Chloride channel modulators; Cystic fibrosis transmembrane conductance regulator modulators; Sodium-hydrogen antiporter modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Feb 2024 Nuvara Therapeutics intends to submit IND application for phase III trial for Constipation in 2024 (Nuvara Therapeutics pipeline, February 2024)
14 Dec 2021 Preclinical trials in Constipation in USA (Enteral) prior to December 2021 (Nuvara Therapeutics pipeline, December 2021)
14 Dec 2021 Nuvara Therapeutics plans phase I trial for Constipation in USA in 2022 (Nuvara Therapeutics pipeline, December 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com